INSUBCONTINENT EXCLUSIVE:
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of
editing tools.The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as
CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more
precise editing tools for genetic material.Rather than get bogged down in the patent dispute that raged over the provenance and ownership of
Martin, Mammoth Biosciences co-founder and chief executive.Chiefly, the company is touting its Cas14 enzyme, which the company says opens up
in-vivo, meaning in live organisms, instead of ex-vivo, or outside of an organism
umpteenth drug gets approved using Crispr and some nuclease named Cas132013, people are going to look back on this patent battle and think,
Discovery, a Cambridge, U.K.-based gene editing technology developer, is using the new tools developed by Mammoth Bioscience to create new
CRISPR tools for Chinese Hamster Ovary cell line editing.That partnership is an example of how Mammoth is thinking about the
industry, including Peter Nell, a co-founder of Casebia (a joint venture between Bayer and CRISPR Therapeutics), who came on board as
chief business officer, and Ted Tisch, a former executive at Synthego and Bio-Rad, who joined the company as chief operating officer.The
company also nabbed $45 million of funding, including investment firms Mayfield, NFX, Verily (the Alphabet subsidiary) and Brook Byers,
Mammoth is the best positioned of the CRISPR development tools, because the company is building a whole platform that customers can license
